Related Experiment Videos
Lectins: reliable differentiation markers in human oligodendrogliomas
J Figols1, J Cervós-Navarro, F F Cruz-Sánchez
1Institute of Neuropathology, Free University of Berlin.
Summary
Glial fibrillary acidic protein (GFAP) and lectin binding, including peanut agglutinin (PNA), can help accurately grade oligodendrogliomas. PNA shows high affinity in well-differentiated tumors, decreasing with differentiation and lost in anaplastic types.
Area of Science:
- Neuro-oncology
- Histopathology
- Biochemistry
Background:
- Oligodendrogliomas are primary brain tumors with varying grades.
- Accurate grading is crucial for prognosis and treatment decisions.
- Distinguishing well-differentiated from anaplastic oligodendrogliomas can be challenging.
Purpose of the Study:
- To investigate the utility of glial fibrillary acidic protein (GFAP) and lectin binding in grading oligodendrogliomas.
- To assess the differential expression of specific lectins in well-differentiated versus anaplastic oligodendrogliomas.
Main Methods:
- Ninety oligodendroglioma tumor samples (43 well-differentiated, 47 anaplastic) were analyzed.
- Immunohistochemical staining was performed using glial fibrillary acidic protein (GFAP).
- Binding patterns of peanut agglutinin (PNA), concanavalin A (Con A), wheat germ agglutinin (WGA), and Ricinus communis agglutinin (RCA-1) were evaluated.
Main Results:
- Peanut agglutinin (PNA) exhibited high affinity to cellular membranes of well-differentiated oligodendrogliomas.
- PNA affinity decreased with differentiation towards astrocytic lines and was absent in anaplastic oligodendrogliomas.
- Concanavalin A (Con A) staining was observed in anaplastic oligodendroglioma cells and reactive astrocytes, primarily in the cytoplasm.
Conclusions:
- Combined analysis of GFAP and lectin binding, particularly PNA and Con A, offers a promising method for accurate oligodendroglioma grading.
- Lectins can serve as valuable biomarkers for differentiating tumor grades.
- This approach may improve diagnostic accuracy and patient management for oligodendrogliomas.